Phase 2
Completed N=110
Topical Amethocaine Gel for Intramuscular Injection in Term Neonates
Source: ClinicalTrials.gov NCT00267111 ↗Enrolled (actual)
110
Serious AEs
0.0%
Results posted
Apr 2012
Primary outcomePrimary: Pain Scores Assessed by Neonatal Facial Action — 14; 18; 30; 44 Percentage of time — p=< 0.05
Summary
This study will examine the efficacy of topical amethocaine gel (Ametop) in decreasing the pain response in term neonates subjected to intramuscular injection for administration of vitamin K.
Study Hypothesis: We believe that topical amethocaine gel will be superior to placebo in decreasing the pain from intramuscular injection in term neonates.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Scores Assessed by Neonatal Facial Action |
14; 18; 30; 44; 70; 75 | < 0.05 sig |
| SECONDARY Visual Analogue Scale |
4.6; 4.6; 5.0; 4.9 | <0.05 sig |
Eligibility Criteria
Inclusion Criteria
- Term neonates > 37 weeks and
- Birth weight > 2500 grams (appropriate for gestational age - AGA) -
Exclusion Criteria
- Neonates with major congenital anomalies
- Neonates with known neurological abnormalities (antenatally diagnosed)
- Neonates who require admission to the neonatal intensive care unit at birth
Data sourced from ClinicalTrials.gov (NCT00267111). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.